GlassScriptPhysician profile
Patience Whitten
NPI 1508321621
$4,985.61
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $712 · 2022: $2,441 · 2023: $1,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,832.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,162.66 | 2021-2023 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,092.72 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $417.39 | 2021-2023 | Entyvio |
| Janssen Biotech, INC. | $282.92 | 2021-2023 | Stelara, Simponi, Remicade |
| Nestle Healthcare Nutrition INC. | $255.45 | 2021-2023 | |
| Genzyme Corporation | $219.17 | 2022-2023 | |
| Qol Medical, LLC | $218.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $171.92 | 2022-2023 | Dificid |
| Pfizer INC. | $156.88 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $154.10 | 2021-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $144.52 | 2022-2023 | Rebyota |
| Gilead Sciences, INC. | $135.44 | 2022-2023 | |
| Amgen INC. | $113.92 | 2022-2023 | Amjevita, Avsola |
| Ironwood Pharmaceuticals, INC | $79.51 | 2022-2023 | Linzess |
| Daiichi Sankyo INC. | $62.29 | 2022-2023 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $58.66 | 2023 | Dupixent |
| Evoke Pharma, INC. | $54.63 | 2023 | Gimoti |
| Ardelyx, INC. | $46.95 | 2023 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.07 | 2023 | Cyltezo |
| Redhill Biopharma INC. | $33.92 | 2021-2022 | |
| Celgene Corporation | $26.98 | 2022-2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $26.54 | 2022 | |
| Lilly USA, LLC | $19.12 | 2023 | |
| Intra-Sana Laboratories | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patience Whitten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.